Your browser doesn't support javascript.
loading
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
Qin, Shukui; Ren, Zhenggang; Meng, Zhiqiang; Chen, Zhendong; Chai, Xiaoli; Xiong, Jianping; Bai, Yuxian; Yang, Lin; Zhu, Hong; Fang, Weijia; Lin, Xiaoyan; Chen, Xiaoming; Li, Enxiao; Wang, Linna; Chen, Chunxia; Zou, Jianjun.
Afiliação
  • Qin S; Cancer Centre of Jinling Hospital, Nanjing, China. Electronic address: qinsk@csco.org.cn.
  • Ren Z; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Meng Z; Minimally Invasive Therapy Center, Shanghai Cancer Center, Fudan University, Shanghai, China.
  • Chen Z; Department of Medical Oncology, Second Hospital of Anhui Medical University, Hefei, China.
  • Chai X; Department of Intervention, Hunan Cancer Hospital, Changsha, China.
  • Xiong J; Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Bai Y; Department of Medical Oncology, Third Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Yang L; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Zhu H; Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Fang W; Department of Medical Oncology, First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Lin X; Department of Medical Oncology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Chen X; Department of Interventional Radiology, Cancer Center, Guangdong Provincial People's Hospital, Guangzhou, China.
  • Li E; Department of Medical Oncology, First Affiliated Hospital of Xi'an Jiaotong University (School of Medicine), Xi'an, China.
  • Wang L; Jiangsu Hengrui Medicine, Shanghai, China.
  • Chen C; Jiangsu Hengrui Medicine, Shanghai, China.
  • Zou J; Jiangsu Hengrui Medicine, Shanghai, China.
Lancet Oncol ; 21(4): 571-580, 2020 04.
Article em En | MEDLINE | ID: mdl-32112738
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Anticorpos Monoclonais Humanizados / Neoplasias Hepáticas Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Anticorpos Monoclonais Humanizados / Neoplasias Hepáticas Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de publicação: Reino Unido